Poststatin Lipid Therapeutics: A Review
References
- Benjamin EJ Virani SS Callaway CW .; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association Circulation 2018 Mar 20 137 12 e67 e492
- Weir HK Anderson RN Coleman King SM Heart Disease and Cancer Deaths - Trends and Projections in the United States, 1969–2020 Prev Chronic Dis 2016 Nov 17 13 E157
- Baigent C Blackwell L Emberson J .; Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Lancet 2010 Nov 13 376 9753 1670 81
- Stroes ES Thompson PD Corsini A Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management Eur Heart J 2015 May 1 36 17 1012 22
- Phan BA Dayspring TD Toth PP Ezetimibe therapy: mechanism of action and clinical update Vasc Health Risk Manag 2012 8 415 27
- Pandor A Ara RM Tumur I Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials J Intern Med 2009 May 265 5 568 80
- Morrone D Weintraub WS Toth PP Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials Atherosclerosis 2012 Aug 223 2 251 61
- Rossebø AB Pedersen TR Boman K .; SEAS Investigators Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 2008 Sep 25 359 13 1343 56
- Baigent C Landray MJ Reith C .; SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 2011 Jun 25 377 9784 2181 92
- Cannon CP Blazing MA Giugliano RP .; IMPROVE-IT Investigators Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes N Engl J Med 2015 Jun 18 372 25 2387 97
- Bohula EA Morrow DA Giugliano RP Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention J Am Coll Cardiol 2017 Feb 28 69 8 911 21
- Lloyd-Jones DM Morris PB Ballantyne CM 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways J Am Coll Cardiol 2017 Oct 3 70 14 1785 822
- Goldstein JL Brown MS Anderson RG Russell DW Schneider WJ Receptor-mediated endocytosis: concepts emerging from the LDL receptor system Annu Rev Cell Biol 1985 1 1 39
- Tavori H Fan D Blakemore JL Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation Circulation 2013 Jun 18 127 24 2403 13
- Sabatine MS Giugliano RP Keech AC .; FOURIER Steering Committee and Investigators Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med 2017 May 4 376 18 1713 22
- Schwartz GG Steg PG Szarek M .; ODYSSEY OUTCOMES Committees and Investigators Alirocumab and cardiovascular outcomes after acute coronary syndrome N Engl J Med. 2018 Nov 7
- ICER [Internet] Boston, MA Institute for Clinical and Economic Review c2018 Evolocumab for treatment of high cholesterol: effectiveness and value—new evidence update; 2017 Sep 11 [accessed 2018 Sep 17]. Available from: https://icer-review.org/wp-content/uploads/2017/06/ICER_PCSK9_NEU_091117.pdf
- ICER [Internet] Boston, MA Institute for Clinical and Economic Review c2018 Alirocumab for treatment of high cholesterol: effectiveness and value—preliminary new evidence update; 2018 Mar 10 [Accessed 2018 Sep 17]. Available from: https://icer-review.org/wp-content/uploads/2018/03/Alirocumab-Preliminary-New-Evidence-Update_03102018.pdf
- Akdim F Stroes ES Sijbrands EJ Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J Am Coll Cardiol 2010 Apr 13 55 15 1611 8
- Carthew RW Sontheimer EJ Origins and mechanisms of miRNAs and siRNAs Cell 2009 Feb 20 136 4 642 55
- Ray KK Landmesser U Leiter LA Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol N Engl J Med 2017 Apr 13 376 15 1430 40
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2018 Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) (ORION-9); 2018 Apr 9 [cited 2018 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03397121
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2018 Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol (ORION-10); 2018 Apr 23 [cited 2018 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03399370
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2018 Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11); 2018 Apr 26 [cited 2018 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03400800
- TIMI Study Group [Internet] Boston, MA TIMI Study Group c2018 HPS-4/TIMI 65 ORION-4l; 2018 [Accessed 2018 Sep 17]. Available from: http://www.timi.org/index.php?page=orion-4
- Bilen O Ballantyne CM Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase Curr Atheroscler Rep 2016 Oct 18 10 61
- Penson P McGowan M Banach M Evaluating bempedoic acid for the treatment of hyperlipidaemia Expert Opin Investig Drugs 2017 Feb 26 2 251 9
- Ballantyne CM Davidson MH Macdougall DE Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial J Am Coll Cardiol 2013 Sep 24 62 13 1154 62
- Gutierrez MJ Rosenberg NL Macdougall DE Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus Arterioscler Thromb Vasc Biol 2014 Mar 34 3 676 83
- Ballantyne CM McKenney JM MacDougall DE Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy Am J Cardiol 2016 117 1928 33
- Ballantyne CM Banach M Mancini GBJ Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study Atherosclerosis 2018 Jun 12
- Clinical Trials [Internet] Bethesda, MD U.S. National Library of Medicine c2018 Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes); 2016 Dec 15 [cited 2018 Oct 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03400800
- Erqou S Kaptoge S Perry PL .; Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 2009 Jul 22 302 4 412 23
- Willeit P Kiechl S Kronenberg F Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study J Am Coll Cardiol 2014 Sep 2 64 9 851 60
- Banach M Lipoprotein (a)-We Know So Much Yet Still Have Much to Learn J Am Heart Assoc 2016 Apr 23 5 4 e003597
- Koschinsky ML Boffa MB Marcovina SM Lipoprotein(a) In Ballantyne CM editor Clinical Lipidology: A Companion to Braunwald's Heart Disease Philadelphia, PA Elsevier Saunders 2015 p 109 27
- Viney NJ Yeang C Yang X Xia S Witztum JL Tsimikas S Relationship between “LDL-C”, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide J Clin Lipidol. 2018 May - Jun 12 3 702 10
- Khera AV Everett BM Caulfield MP Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) Circulation 2014 Feb 11 129 6 635 42
- Kotani K Banach M Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9 J Thorac Dis 2017 Jan 9 1 E78 E82
- Ooi EM Watts GF Chan DC Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus Arterioscler Thromb Vasc Biol 2015 Dec 35 12 2686 93
- Viney NJ van Capelleveen JC Geary RS Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials Lancet 2016 Nov 5 388 10057 2239 53
- Stefanutti C Thompson GR Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances Curr Atheroscler Rep 2015 Jan 17 1 465
- Gaudet D Alexander VJ Baker BF Antisense Inhibition of Apolipo-protein C-III in Patients with Hypertriglyceridemia N Engl J Med 2015 Jul 30 373 5 438 47
- Dewey FE Gusarova V Dunbar RL Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease N Engl J Med 2017 Jul 20 377 3 211 21
DOI: https://doi.org/10.14797/mdcj-15-1-32 | Journal eISSN: 1947-6108
Language: English
Page range: 32 - 38
Published on: Jan 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2019 Xiaoming Jia, Patrick Lorenz, Christie M. Ballantyne, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.